Plasma fibroblast growth factor 21 is associated with subsequent growth in a cohort of underweight children in Bangladesh

Current Developments in Nutrition

Volumn 3, Issue 5, 2019, Pages

  Arndt, Michael B ^a,c   Richardson, Barbra A ^a   Mahfuz, Mustafa ^d   Ahmed, Tahmeed ^d,e   Haque, Rashidul ^d   Gazi, Md Amran ^d   John Stewart, Grace C ^a,b   Denno, Donna M ^a,b,e   Scarlett, Jarrad M ^f   Walson, Judd L ^a,b,e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c PATH   (United States)

^d INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^e The Childhood Acute Illness and Nutrition Network (CHAIN)   (Kenya)

^f SEATTLE CHILDREN S HOSPITAL   (United States)

Author keywords

FGF21; Growth hormone resistance; Protein deficiency; Stunting; Supplementation; Undernutrition; Underweight

Indexed keywords

EID: 85067684366     PISSN: None     EISSN: 24752991     Source Type: Journal    
DOI: 10.1093/cdn/nzz024     Document Type: Article

References (40)

1. de Onis M, Blössner M, Borghi E. Prevalence and trends of stunting among pre-school children, 1990–2020. Public Health Nutr 2012;15(1):142–8.
2. Black R, Victora C, Walker S, Bhutta Z, Christian P, Onis M, Ezzati M, Grantham-McGregor S, Katz J, Martorell R, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. Lancet 2013;382(9890):427–51.
3. de Onis M, Blössner M. WHO global database on child growth and malnutrition. Geneva: World Health Organization; 1997.
4. Dewey KG, Adu-Afarwuah S. Systematic review of the efficacy and effectiveness of complementary feeding interventions in developing countries. Matern Child Nutr 2008;4(Suppl 1):24–85.
5. Boron WF, Boulpaep EL. Medical physiology: a cellular and molecular approach. Philadelphia, PA: Saunders Elsevier; 2012.
6. Fazeli P, Klibanski A. Determinants of GH resistance in malnutrition. J Endocrinol 2014;220(3):R57–65.
7. DeBoer MD, Scharf RJ, Leite AM, Férrer A, Havt A, Pinkerton R, Lima AA, Guerrant RL. Systemic inflammation, growth factors, and linear growth in the setting of infection and malnutrition. Nutrition 2017;33:248–53.
8. Kubicky R, Wu S, Kharitonenkov A, Luca F. Role of fibroblast growth factor 21 (FGF21) in undernutrition-related attenuation of growth in mice. Endocrinology 2012;153(5):2287–95.
9. Inagaki T, Lin V, Goetz R, Mohammadi M, Mangelsdorf D, Kliewer S. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab 2008;8(1):77–83.
10. Wu S, Grunwald T, Kharitonenkov A, Dam J, Jockers R, Luca F. Increased expression of fibroblast growth factor 21 (FGF21) during chronic undernutrition causes growth hormone insensitivity in chondrocytes by inducing leptin receptor overlapping transcript (LEPROT) and leptin receptor overlapping transcript-like 1 (LEPROTL1) expression. J Biol Chem 2013;288(38):27375–83.
11. Touvier T, Conte-Auriol F, Briand O, Cudejko C, Paumelle R, Caron S, Baugé E, Rouillé Y, Salles JP, Staels B, et al. LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice. J Clin Invest 2009;119(12):3830–8.
12. Wu S, Levenson A, Kharitonenkov A, Luca F. Fibroblast growth factor 21 (FGF21) inhibits chondrocyte function and growth hormone action directly at the growth plate. J Biol Chem 2012;287(31):26060–7.
13. Guasti L, Silvennoinen S, Bulstrode NW, Ferretti P, Sankilampi U, Dunkel L. Elevated FGF21 leads to attenuated postnatal linear growth in preterm infants through GH resistance in chondrocytes. J Clin Endocrinol Metab 2014;99(11):E2198–206.
14. Laeger T, Henagan TM, Albarado DC, Redman LM, Bray GA, Noland RC, Münzberg H, Hutson SM, Gettys TW, Schwartz MW, et al. FGF21 is an endocrine signal of protein restriction. J Clin Invest 2014;124(9):3913–22.
15. Gosby AK, Lau NS, Tam CS, Iglesias MA, Morrison CD, Caterson ID, Brand-Miller J, Conigrave AD, Raubenheimer D, Simpson SJ. Raised FGF-21 and triglycerides accompany increased energy intake driven by protein leverage in lean, healthy individuals: a randomised trial. PLoS One 2016;11(8):e0161003.
16. Fazeli PK, Lun M, Kim SM, Bredella MA, Wright S, Zhang Y, Lee H, Catana C, Klibanski A, Patwari P, et al. FGF21 and the late adaptive response to starvation in humans. J Clin Invest 2015;125(12):4601–11.
17. Mericq V, De Luca F, Hernandez MI, Peña V, Rossel K, Garcia M, Avila A, Cavada G, Iñiguez G. Serum fibroblast growth factor 21 levels are inversely associated with growth rates in infancy. Horm Res Paediatr 2014;82(2):324–31.
18. Keusch GT, Denno DM, Black RE, Duggan C, Guerrant RL, Lavery JV, Nataro JP, Rosenberg IH, Ryan ET, Tarr PI, et al. Environmental enteric dysfunction: pathogenesis, diagnosis, and clinical consequences. Clin Infect Dis 2014;59(suppl 4):S207–S12.
19. Arndt MB, Walson JL. Enteric infection and dysfunction—a new target for PLOS Neglected Tropical Diseases. PLoS Negl Trop Dis 2018;12(12): e0006906.
20. McGrath CJ, Arndt MB, Walson JL. Biomarkers to stratify risk groups among children with malnutrition in resource-limited settings and to monitor response to intervention. Horm Res Paediatr 2017;88(1):111–17.
21. Ahmed T, Mahfuz M, Islam MM, Mondal D, Hossain MI, Ahmed AS, Tofail F, Gaffar SA, Haque R, Guerrant RL, et al. The MAL-ED cohort study in Mirpur, Bangladesh. Clin Infect Dis 2014;59(suppl 4):S280–S6.
22. The MAL-ED Network Investigators. The MAL-ED Study: a multinational and multidisciplinary approach to understand the relationship between enteric pathogens, malnutrition, gut physiology, physical growth, cognitive development, and immune responses in infants and children up to 2 years of age in resource-poor environments. Clin Infect Dis 2014;59(suppl 4): S193–206.
23. Choudhury N, Bromage S, Alam MA, Shamsir Ahmed AM, Munirul Islam M, Iqbal Hossain M, Mahfuz M, Mondal D, Haque R, Ahmed T. Intervention study shows suboptimal growth among children receiving a food supplement for five months in a slum in Bangladesh. Acta Paediatr 2016;105(10):e464–73.
24. Ahmed T, Choudhury N, Hossain M, Tangsuphoom N, Islam M, Pee S, Steiger G, Fuli R, Sarker SAM, Parveen M, et al. Development and acceptability testing of ready-to-use supplementary food made from locally available food ingredients in Bangladesh. BMC Pediatr 2014;14:164.
25. WHO. Guideline. Updates on the management of severe acute malnutrition in infants and children. Geneva: World Health Organization; 2013.
26. Richard SA, McCormick BJJ, Miller MA, Caulfield LE, Checkley W. Modeling environmental influences on child growth in the MAL-ED cohort study: opportunities and challenges. Clin Infect Dis 2014;59(suppl 4): S255–S60.
27. McCormick BJ, Lee GO, Seidman JC, Haque R, Mondal D, Quetz J, Lima AAM, Babji S, Kang G, Shrestha SK, et al. Dynamics and trends in fecal biomarkers of gut function in children from 1–24 months in the MAL-ED study. Am J Trop Med Hyg 2017;96(2):465–72.
28. Guerrant RL, Leite AM, Pinkerton R, Medeiros PH, Cavalcante PA, DeBoer M, Kosek M, Duggan C, Gewirtz A, Kagan JC, et al. Biomarkers of environmental enteropathy, inflammation, stunting, and impaired growth in children in Northeast Brazil. PLoS One 2016;11(9):e0158772.
29. Kosek M, Guerrant RL, Kang G, Bhutta Z, Yori PP, Gratz J, Gottlieb M, Lang D, Lee G, Haque R, et al. Assessment of environmental enteropathy in the MAL-ED cohort study: theoretical and analytic framework. Clin Infect Dis 2014;59(suppl 4):S239–S47.
30. Driskell WJ, Neese JW, Bryant CC, Bashor MM. Measurement of vitamin A and vitamin E in human serum by high-performance liquid chromatography. J Chromatogr 1982;231(2):439–44.
31. Kosek M, Haque R, Lima A, Babji S, Shrestha S, Qureshi S, Amidou S, Mduma E, Lee G, Yori PP, et al. Fecal markers of intestinal inflammation and permeability associated with the subsequent acquisition of linear growth deficits in infants. Am J Trop Med Hyg 2013;88(2):390–6.
32. Victora C, Onis M, Hallal P, Blössner M, Shrimpton R. Worldwide timing of growth faltering: revisiting implications for interventions. Pediatrics 2010;125(3):e473–80.
33. Wang AZ, Shulman RJ, Crocker AH, Thakwalakwa C, Maleta KM, Devaraj S, Manary MJ, Trehan I. A combined intervention of zinc, multiple micronutrients, and Albendazole does not ameliorate environmental enteric dysfunction or stunting in rural Malawian children in a double-blind randomized controlled trial. J Nutr 2016;147(1):97–103.
34. Stephenson KB, Agapova SE, Divala O, Kaimila Y, Maleta KM, Thakwalakwa C, Ordiz MI, Trehan I. Complementary feeding with cowpea reduces growth faltering in rural Malawian infants: a blind, randomized controlled clinical trial. Am J Clin Nutr 2017;106(6):1500–7.
35. Cheng WD, Wold KJ, Bollinger LB, Ordiz MI, Shulman RJ, Maleta KM, Manary MJ, Trehan I. Supplementation with lactoferrin and lysozyme ameliorates environmental enteric dysfunction: a double-blind, randomized, placebo-controlled trial. Am J Gastroenterol 2019;114(4):671–8.
36. van der Merwe LF, Moore SE, Fulford AJ, Halliday KE, Drammeh S, Young S, Prentice AM. Long-chain PUFA supplementation in rural African infants: a randomized controlled trial of effects on gut integrity, growth, and cognitive development. Am J Clin Nutr 2013;97(1):45–57.
37. Gälman C, Lundåsen T, Kharitonenkov A, Bina HA, Eriksson M, Hafström I, Dahlin M, Amark P, Angelin B, Rudling M. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARα activation in man. Cell Metab 2008;8(2):169–74.
38. Keusch GT, Rosenberg IH, Denno DM, Duggan C, Guerrant RL, Lavery JV, Tarr PI, Ward HD, Black RE, Nataro JP. Implications of acquired environmental enteric dysfunction for growth and stunting in infants and children living in low- and middle-income countries. Food Nutr Bull 2013;34(3):357–64.
39. Kosek MN; The MAL-ED Network Investigators. Causal pathways from enteropathogens to environmental enteropathy: findings from the MAL-ED Birth Cohort Study. EBioMedicine 2017;18:109–17.
40. Strygler B, Nicar MJ, Santangelo WC, Porter JL, Fordtran JS. α1-antitrypsin excretion in stool in normal subjects and in patients with gastrointestinal disorders. Gastroenterology 1990;99(5):1380–7.